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Abstract 
Aims: Functional capacity is an important endpoint for therapies oriented to older adults with 
cardiovascular diseases. The literature on predictors of exercise capacity is sparse in the elderly 
population. In a longitudinal European study on effectiveness of cardiac rehabilitation (CR) of 
seven European countries in elderly (>65 years) coronary artery disease (CAD) or valvular heart 
disease (VDH) patients, predictors for baseline exercise capacity were determined, and reference 
ranges for elderly cardiac patients provided. 
Methods: Mixed models were performed in 1282 patients (mean age 72.9±5.4 years, 79% male) 
for peak oxygen consumption relative to weight (peak VO2; ml/kg/min) with centre as random 
factor and patient anthropometric, demographic, social, psychological, and nutritional parameters, 
as well as disease aetiology, procedure, comorbidities and cardiovascular risk factors (CVRF) as 
fixed factors.  
Results: The most important predictors for low peak VO2 were coronary artery bypass grafting or 
valve surgery, low resting forced expiratory volume, reduced left ventricular ejection fraction, 
nephropathy and peripheral arterial disease. Each cumulative comorbidity or CVRF reduced 
exercise capacity by 1.7 ml/kg/min and 1.1 ml/kg/min, respectively. Males had a higher peak VO2 
per body mass but not per lean mass. Haemoglobin was significantly linked to peak VO2 in both 
surgery and non-surgery patients. 
Conclusions:  Surgical procedures, cumulative comorbidities and CVRFs were the factors with 
the strongest relation to reduced exercise capacity in the elderly. Expression of peak VO2 per lean 
mass rather than body mass allows a more appropriate comparison between sexes. Haemoglobin is 
strongly related to peak VO2 and should be considered in studies assessing exercise capacity, 
especially in studies on patients after cardiac surgery. 
Abstract word count: 263 
Key words: cardiac rehabilitation, cardiopulmonary exercise testing, exercise capacity, peak VO2 
Netherlands Trial Register, Trial NL5166:   https://www.trialregister.nl/trial/5166 
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Abbreviation list 
CVD cardiovascular disease 
CAD coronary artery disease 
CR cardiac rehabilitation 
VHD valvular heart disease 
peak VO2 peak oxygen consumption 
CVRF cardiovascular risk factors 
PCI percutaneous intervention 
CABG coronary artery bypass grafting 
BMI body mass index 
LVEF Left ventricular ejection fraction 
MET Metabolic equivalent 
CPET cardiopulmonary exercise testing 
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Introduction 
Exercise capacity has been found to be reduced in patients with cardiovascular disease (CVD) 
compared to healthy people of the same age.(1) The reason for this may be linked to the coronary 
artery disease (CAD) itself, a reduced left ventricular function caused by CAD, the often associated 
endothelial dysfunction,(2) or secondary to comorbidities commonly associated with CAD, such 
as diabetes,(3) nephropathy, and/or peripheral vascular disease(4), or cardiovascular risk 
factors.(5)  
In CAD patients, heart failure patients, diabetic and nephropathy patients, as well as in the generally 
healthy population, those with higher exercise capacity have better prognosis.(6, 7) This is why in 
many studies exercise capacity has served as a surrogate measure for hard outcomes, which require 
longer follow-up times. Further, cardiac rehabilitation (CR) has been shown to increase exercise 
capacity and result in improved prognosis (8, 9). The American Heart Association has recently 
recommended prioritizing functional capacity as a principal endpoint for therapies oriented to older 
adults with cardiovascular disease.(10) However, the literature on predictors of exercise capacity 
is sparse in elderly CAD patients. 
The present study aims firstly, to identify predictors for peak oxygen consumption (peak VO2) at 
the start of CR. Knowledge on independently influencing factors for exercise capacity is an 
important prerequisite for improving future study designs by providing information on the 
important confounding variables which, firstly, will need to be measured, and, secondly, included 
in the analyses. Secondly, we aimed to quantify the effects of single and cumulative comorbidities 
and cardiovascular risk factors (CVRF) on exercise capacity. Thirdly, we aimed at composing 
reference ranges for elderly male and female patients with CAD and valvular heart disease (VHD). 
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Methods 
The EU-CaRE study is a prospective multi centre- and country cohort study with eight participating 
CR units in seven countries (Denmark, France, Germany, the Netherlands, Italy, Spain and 
Switzerland) aiming to assess the effectiveness and sustainability of current CR in Europe in elderly 
patients.(11) The study was approved by all relevant medical ethics committees and registered at 
register.nl (NL5166). All participants gave written informed consent before they were included in 
the study. 
Study population 
Patients commencing CR after a recent acute coronary syndrome (ACS), coronary 
revascularization (percutaneous intervention=PCI, or coronary artery bypass grafting=CABG), 
surgical or percutaneous treatment for valvular disease, or documented CAD defined by standard 
non-invasive or invasive methods were included. Patients were assessed at baseline before 
commencing CR, after completing the CR program and at 1-year follow-up. For the present study, 
only baseline data is used. Changes on peak VO2 will be analysed elsewhere. 
Statistical analysis 
All statistics were performed with R (Version 3.5.1, R Core Team, 2017). A list of potential 
predictors included in the model is provided in the online appendix. A mixed linear model was 
performed for peak VO2 [ml/min/kg] with centre as random variable and all potential predictors 
as independent variables (lme function from nlme package). Collinearities were assessed by 
generalized variance inflation factors (GVIF from car package). Non-significant variables were 
eliminated from the model manually by individually removing the variable with the largest p-value 
until any insignificant (p>0.01) parameters were removed from the model. Due to multiple testing, 
alpha was set at 0.01 for all analyses. For the resulting model, diagnostics were performed for 
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checking fulfilment of model assumptions. In case of presence of assumption violations, a more 
flexible GAMLSS model (Generalized Additive Models for Location, Scale and Shape) was 
performed using the gamlss package. In order to reduce potential sex differences, the same model 
was performed for the dependent variable peak VO2 per lean body mass.  
Sub-analyses were performed entering haemoglobin as an independent variable for the 
subpopulation of patients with available haemoglobin data. Further, the same models as described 
above were performed for the more homogeneous subpopulation of PCI patients. 
To assess the effect of single CVRFs on weight adjusted peak VO2, we performed mixed linear 
models adjusting only for age and sex (fixed factors) and centre (random factor) in order to avoid 
adjusting for spurious collinearities between CVRFs and comorbidities and to have a direct 
comparison between the different comorbidities and CVRFs.  
Data collection 
The following data were registered at baseline: indication for CR (index event) and time from index 
event to CR entry testing. Further baseline data included demographic and socioeconomic factors, 
cardiac symptoms assessed by the Canadian Cardiac Society grading of angina (CCS), 
cardiovascular risk factors (CVRF) as well as comorbidities, gathered through hospital records, 
interviewing, questionnaires and clinical assessment. 
The clinical assessment of patients included cardiopulmonary exercise testing (CPET) or 
alternatively six-minute walk test in patients not able to perform a CPET, blood pressure, body 
mass index (BMI), waist-to-hip ratio, lean body mass assessed by skin fold measurement,(12) 
spirometry and electrocardiogram. Left ventricular ejection fraction (LVEF) was from hospital 
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records. Haemoglobin was determined from a blood sample taken between index procedure and 
baseline visit.  
To assess physical activity before index event, patients were asked on how many days per week 
they were doing more more than 30 min of moderate exercise. Questionnaires were used to assess 
quality of diet (MEDAS), quality of life (SF-36v2), degree of anxiety (GAD-7) and depression 
(PHQ-9). 
CPETs were performed on a cycle ergometer with an individualized ramp protocol aiming to 
achieve voluntary exhaustion within 8 to 12 min of ramp duration. Peak VO2 of all CPETs were 
determined at the core lab (Uni Bern) by an automated procedure on raw data files using MALTAB 
software from MathWorks®. The highest 30s moving average was considered as peak VO2. Visual 
quality control was performed by one experienced operator (TM) and in case of doubtful quality 
by a second operator (MW). Gas measurements were excluded from the analysis in case of 
suspected mask leakage or equipment failure, as well as if the ramp duration was less than 3 min 
(unreliable due to the delayed response in oxygen uptake with increasing workload). In these cases, 
peak VO2 was estimated from the maximum workload [Watt] using a recently proposed 
formula.(13) Likewise, peak VO2 was estimated by the ASCM formula for the six-minute walk 
test (4.948+0.02*distance). Peak VO2 was also expressed as metabolic equivalent (MET, =3.5 
ml/kg/min VO2). 
Results 
The final model included 1282 of 1633 patients (number of cases reduced due to missing data in 
any of the included variables). Peak VO2 was measured from 1175 CPETs and calculated from 83 
ergometries and 24 six-minute walk test. A summary of the main characteristics of the study 
population is given in Table 1.  
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Collinearities were weak and GVIFs below 2, except for BMI and waist circumference with a GVIF 
of 3.87 and 3.89, respectively. Consequently, we omitted waist circumference (because of more 
missing data) from the model to prevent the mutual weakening of these two variables within the 
model. Twenty-two predictors remained in the model with centre as random factor. This resulting  
model explained 52% of the total variance in peak VO2. Because the mixed linear model violated 
the assumptions of kurtosis and homoscedasticity, we also performed a GAMLSS model. Mean 
effects of this model are presented in Figure 1. The following variables were significant: Age, male 
sex, BMI, FEV1, LVEF, diastolic BP, resting heart rate, beta blocker, index procedure, angina 
pectoris, other complaints (pain or palpitations that interfere with exercise), nephropathy and 
peripheral arterial disease. Atrial fibrillation, diabetes mellitus, hypertension, physical activity, and 
mental component score (Figure 1). The interaction between index procedure and lag time from 
index event to exercise testing as well as the interaction between age and sex were entered into the 
model, but were not significant. The output of the model is also presented numerically in 
Supplement Table 1 for pooled sexes and in Supplement Table 2 and 3 for both sexes individually. 
In the model for the subpopulation with available haemoglobin data (model including 1033 
patients), haemoglobin was significant (Figure 2). Haemoglobin levels explained some of the 
differences between the groups with different index procedures (CABG and valve surgery being 
lower than PCI and no procedure). However, haemoglobin was also a significant predictor for peak 
VO2 in the subgroup analysis of the PCI patients only (model including 541 patients, Figure 2). 
Effects of comorbidities and CV risk factors adjusted for age, sex, and centre only are shown in 
Table 2. Each additional comorbidity reduced peak VO2 by 1.7 ml/kg/min or half a MET and each 
additional CVRF by 1.1 ml/kg/min. In the 1333 patients with available haemoglobin data, anaemia 
reduced exercise capacity by 3.23 ml/kg/min (almost 1 MET) (Table 2). 
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Reference ranges for our 1230 male and 352 female patients with CAD or VHD between age 65 
and 90 are shown in Figure 3. 
 
Discussion 
This is the first study to identify predictors for exercise capacity in a large cohort of elderly CAD 
and/or VHD patients. The most important predictors were age, CABG, valve surgery, reduced 
LVEF, nephropathy and PAD. Each additional comorbidity or CVRF reduced exercise capacity by 
1.7 and 1.1 ml/kg/min, respectively. Female sex was also associated with lower peak VO2, 
however, this difference disappeared when peak VO2 was expressed per lean mass rather than body 
weight. Resting forced expiratory volume in the first second and haemoglobin were strongly 
associated with peak VO2. Finally, our data set provides reference ranges from 1582 CAD and 
VHD elderly patients commencing CR. 
Predictors for peak VO2 
In line with our results, the largest existing study that has assessed predictors of exercise capacity 
in 2869 patients (mean age 62 years) commencing CR has found CABG, angina at stress testing 
and hypertension associated with peak VO2(14) and another large study in nearly 1000 younger 
CAD patients (mean age 63 years) found sex, age, BMI, NYHA class, resting and peak heart rate, 
beta blocker and fasting blood glucose as significant predictors, (15) . Likewise, in 171 CAD 
patients from South Africa age, sex, ejection fraction, and forced vital capacity were found to be 
predictors of exercise capacity.(16)  
In our study, females had an 11% lower peak VO2 relative to body weight compared to males 
despite multivariate adjustment. This sex difference disappeared completely when peak VO2 was 
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expressed relative to lean mass. Effects of other factors remained very similar in the model for peak 
VO2 per lean mass. Relating VO2 to lean rather than body mass has previously been found to be 
superior (17) and to reduce sex differences.(18) Sex differences in absolute peak VO2 (ml/min) 
have been found to diminish with increasing age in elderly sedentary people, due to the fact that 
men have a steeper age-related decrease in VO2 peak.(19) However, we found only a modest age 
decline in peak VO2 with 0.95 ml/kg/min per decade and no significant difference between males 
and females. This is in contrast to a previous study on patients entering CR, which showed a decline 
of 2.4 ml/kg/min per decade in males and 1.16 in females.(5) The same study found that peak VO2 
was significantly influenced by the index-procedure with CABG patients having the lowest 
exercise capacity. We found that haemoglobin largely accounted for the difference in peak VO2 
between index procedures with open surgery (CABG and VHD patients, of whom 87% were 
anaemic) and minimally invasive or non-surgical procedures (of whom 25% were anaemic). Only 
few prior studies have reported exercise capacity and haemoglobin values in CAD patients (16, 
20), in contrast to some large studies on predictors of peak VO2 (14, 15) and large exercise trials 
(21) who did not report haemoglobin. This is despite the fact that haemoglobin has been found to 
be an important contributor to oxygen uptake and exercise capacity as it is responsible for the 
blood’s capacity to transport oxygen from the lung to the muscle cells.(22, 23) Outcome in CAD 
patients has also been found to be related to haemoglobin levels,(24, 25) possibly because 
haemoglobin may be a marker of other chronic diseases.(26) However, low haemoglobin levels 
caused by blood loss during surgery are likely to be restored with time and will be accompanied 
by some spontaneous recovery of exercise capacity, which should not mistakenly be ascribed to 
the exercise-training effect of CR. 
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Beta blockers were associated with lower exercise capacity, most likely mediated via a decreased 
maximal heart rate. Acute experiments with beta blockers in heart patients have led to a decrease 
in maximal heart rate of over 20 bpm and to a lesser extend in peak VO2.(27) Conversely, in heart 
failure patients, the decrease in maximal heart rate by beta blockers has not been found to decrease 
exercise capacity(28). In our study, the association between beta blocker use and lower peak VO2 
may either be due to a reduction in maximal heart rate with beta blocker or by patient selection 
with more severe CAD to beta blocker prescription.  
FEV1 and FVC are measured during resting spirometry, and are obtainable with minimal 
requirements for time, equipment and patient collaboration. FVC has previously been shown to 
correlate with peak exercise capacity in CAD patients.(16) FEV1, closely linked to FVC has been 
found to be an important predictor of peak VO2. Contrary to the generation 100 study,(29) in our 
study in both males and females there was a linear relationship with FEV1 across the full range of 
peak VO2 values (r=0.54). While physical training would concomitantly increase skeletal and 
respiratory muscle function, this finding lends room to speculations on effectiveness of respiratory 
training for increasing exercise capacity, especially in patients unable to exercise. 
Most comorbidities and CVRF recorded in the present study were associated with lower VO2 peak 
when adjusted for age and sex as fixed effect and centre as random effect only (Table 2). The 
largest effects were found for nephropathy, peripheral arterial disease, atrial fibrillation, diabetes 
mellitus, obesity and inactivity. The addition of each comorbidity or CVRF was associated with a 
decrease of 1.7 and 1.1 ml/kg/min, respectively. This may be put in perspective with the finding 
that the loss of each MET is associated with a 13% increase in all-cause mortality rate and a 15% 
increase in CAD events.(30) Previous studies assessing the associations between CVRF and 
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comorbidities with peak VO2 were performed in much smaller populations and, possibly as a 
consequence, only found some of these factors to be significant.(31, 32) 
Reference ranges 
There is a paucity of data on peak VO2 in the elderly, and particularly in elderly with CAD or 
VHD. Existing reference populations have included relatively few subjects older than 65 years.(33-
35) The HUNT Fitness study included 1046 healthy elderly dwellers older than 60 years, but only 
269 of them were older than 70 years (mean peak VO2 of  26.5 ± 4.7 (SD) for females and 34.1 ±7 
ml/kg/min for males)(5). The Generation 100 study also provided reference ranges for 297 older 
volunteers (mean age 73 years) with a history of cardiovascular disease.(1) This diseased 
population with a mean age of 72.9 years had a mean peak VO2 on the treadmill of 29.3 ± 6.9 
ml/kg/min, which was considerably higher than the median of approximately 18 ml/kg/min of our 
reference range in males for age 73. Our reference ranges are comparable to a previous American 
study on 2896 patients (mean age 61 years, 724 patients  ≥70 years) entering CR after a recent 
acute cardiac event and confirm the low exercise capacity in elderly patients commencing CR. The 
reference ranges shown in Figure 3 provide useful data for clinicians caring for elderly patients 
acutely after CAD or VHD and researchers planning clinical studies in these populations. Figure 4 
illustrates the importance of the most common CVRF and comorbidities in reducing exercise 
capacity, by showing peak VO2 of our population with and without anemia and diabetes compared 
to the healthy volunteers of the HUNT study. 
Strengths 
The strengths of the current study are the large sample size and comprehensiveness of data on 
patient and disease characteristics, physical function, CVRF and comorbidities, which allowed the 
direct comparison between effect sizes of different predictors for exercise capacity. Automatic 
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processing of CPETs by one core lab improved comparison of peak VO2 data from different 
centres. Further, the assessment of skinfold thickness and calculation of peak VO2 per lean body 
mass allowed a more appropriate comparison of males and females. The inclusion of haemoglobin 
partly explained the lower exercise capacity of surgery patients and allowed the quantification of 
an increase in VO2 peak of 0.73 ml/min/kg per increase in 1 mmol/l haemoglobin.  
Limitations 
Our model explained 52% of the total variance in peak VO2, leaving a considerable part of variance 
unexplained. Five percent of the variance could uniquely be explained by centre differences, 
probably due to patient characteristics not directly assessed in the present study. Given the 
explorative identification of influencing factors on peak VO2, statistical significance has to be 
interpreted with caution. However, the identified predictive variables were mostly highly 
significant (p<0.0001) and robust to changes in the model specification. Reproducibility and 
accuracy of peak VO2 measurements, resting heart rate, BP, skinfold thickness, FVC and FEV1 
have known limitations. The model identifying predictors for peak VO2 was based on 1282 cases 
out of a total data set of 1582 VO2 peak data. Nevertheless, we compared the complete peak VO2 
data to the peak VO2 data included in the model within each centre and found excellent agreement 
(differences < 3%). Additionally, we imputed the dataset by multiple imputation and computed an 
automatic stepwise backward modelling, which resulted in a model comparable to that shown in 
Figure 2. Methods and resulting models of these additional analyses are provided in Supplement 
Figure 1. The model included data from 107 patients with calculated rather than measured peak 
VO2 values. This approximation has previously been found to be valid.(13, 36). 
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Conclusions 
Parameters associated with disease severity and surgical procedures were the strongest predictors 
for exercise capacity in elderly CAD patients. For each cumulative comorbidity or CVRF peak 
VO2 decreased by 0.5 and 0.3 MET respectively, while the age-associated decline in VO2 peak 
was small in this population of elderly CAD patients. It is more appropriate to express exercise 
capacity relative to lean body mass rather than to body mass when males are compared to females. 
Due to the considerable large proportion of elderly patients with anemia and the direct physiologic 
link with peak VO2, routine measurement of haemoglobin in elderly patients is recommended and 
should always be included in studies on exercise capacity. FEV1 may serve as an easily obtainable 
surrogate measure of exercise capacity in the elderly population with CVD.  
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Figure legends 
Figure 1: Mean effects of the GAMLSS model for peak VO2 per body weight including data of 
1282 patients. Filled circles display mean effects with 99% confidence intervals. The orange 
triangle shows the sex effect of the corresponding model for peak VO2 per lean body weight as 
dependent variable, calculated by formula based on body weight and skinfold thickness. Please 
note that the other effects of the model for peak VO2 per lean body weight were comparable to the 
effects in the model for peak VO2 per body weight and are not shown. The model included 
continuous, binary and categorical independent variables. For categorical variables reference 
category is indicated.  
BP, blood pressure; CABG, coronary artery bypass graft; FEV1, forced expiratory volume in the 
first second; PCI, percutaneous intervention; SF-36, Short Form Survey 
Figure 2: Mean effects of the GAMLSS model for peak VO2 per body weight for the 
subpopulation of 1033 patients with available haemoglobin data. Filled circles depict mean effects 
with 99% confidence intervals of patients with different index procedures. The orange triangles 
with 99% dashed index intervals depict mean effects of the same model for the 541 patients with 
PCI only. The model included continuous, binary and categorical independent variables. For 
categorical variables reference category is indicated. 
BP, blood pressure; CABG, coronary artery bypass graft; FEV1, forced expiratory volume in the 
first second; PCI, percutaneous intervention; SF-36, Short Form Survey 
Figure 3: Reference ranges of peak VO2 values of 1230 male and 352 female CAD or VHD 
patients. Lines indicate percentiles. Mean peak VO2 by age is estimated by 26.03 – 0.17 × age 
[years] for females and 30.51 – 0.19 × age [years] for males.  
20 
 
Figure 4: Medians and interquartile range of peak oxygen consumption according to age are shown 
for three male subgroups of the EU-CaRE study compared with an illustration of a healthy male 
population from the HUNT study (mean and standard deviation). 
* Aspenes ST, Nilsen TI, Skaug EA, Bertheussen GF, Ellingsen O, Vatten L, et al. Peak oxygen 
uptake and cardiovascular risk factors in 4631 healthy women and men. Medicine and science in 
sports and exercise. 2011;43(8):1465-73. This study has determined peak VO2 on a treadmill, 
which results in slightly higher VO2 values compared to cycle ergometry. 
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Table 1: Characteristics of the 1282 patients included in the final multivariate model.    
Variable N (%)  Mean (SD) 
Age [y]  72.9 (5.4) 
Male Sex 1011 (79%)  
Caucasian Ethnicity 1262 (98%)  
Peak VO2 [ml/kg/min]  16.1 (4.8) 
Body mass index  [kg/m2]  27.3 (4.0) 
Ejection Fraction [%]   
 >55 753 (59%)  
 45-55 327 (26%)  
 35-44 154 (12%)  
 <35 48 (4%)  
Acute Coronary Syndrome 702 (55%)  
Procedure   
 PCI 706 (55%)  
 None 74 (6%)  
 Valve 135 (10%)  
 
CABG 
 
367 (29%)  
Center   
 Zwolle 202 (16%)  
 Copenhagen 179 (14%)  
 Paris 128 (10%)  
 Bern 147 (11%)  
 Santiago 194 (15%)  
 Ludwigshafen 214 (17%)  
 Parma 193 (15%)  
 Nijmegen 25 (2%)  
CABG, coronary artery bypass grafting; PCI, percutaneous 
intervention; SD, standard deviation; Valve, valve replacement; 
VO2, oxygen consumption 
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Table 2: Effects (estimates) for comorbidities and cardiovascular risk factors of mixed linear 
models for peak VO2 (ml/min/kg) adjusted for age and sex as fixed factors and center as random 
factor including 1498 cases. Estimates depict the mean difference between patients with versus 
those without each factor, for cumulative comorbidities/cardiovascular risk factors it is the 
increment per additional comorbidity/risk factor. Percentages indicate the population with the 
comorbidity/CV risk factor. 
 Variable Proportion 
with the risk 
factor 
Coefficient (99% CI) 
 
Comorbidities:      
 Nephropathy  7.6% -2.94 (-4.00; -1.89) * 
 Peripheral artery disease 7.4% -2.17 (-3.24; -1.10) * 
 Atrial Fibrillation 6.8% -2.06 (-3.18; -0.95) * 
 Diabetes Mellitus 23.5% -2.10 (-2.75; -1.45) * 
 COPD 6.4% -1.69 (-2.83; -0.55) * 
 Obstructive sleep apnoea 2.4% -1.52 (-3.33;  0.30) * 
 Depression 2.7% -1.32 (-3.05;  0.40)  
 TIA/ CVA diagnosed by 
neurologist 
6.3% -1.08 (-2.24;  0.08)  
 Rheumatoid Arthritis 1.9% -0.99 (-3.06;  1.08)  
 Cumulative Comorbidities §  -1.71 (-2.06; -1.36) * 
 Anemia# 50.7% -3.23 
 
(-3.85; -2.61) 
 
* 
Cardiovascular Risk Factors:     
 Obesity 22.7% -2.16 (-2.84; -1.49) * 
 Hypertension 66.9% -1.69 (-2.29; -1.10) * 
 Inactivity †     
 No activity 22.1% -2.02 (-2.78; -1.24) * 
 <5 days 32.5% -0.64 (-1.32;  0.03)  
 Smoking ‡     
 Current smoking 9.1% -1.08 (-2.09; -0.07) * 
 Former smoking 16.0% -0.96 (-1.74; -0.18) * 
 Dyslipidemia 67.6% -0.56 (-1.18;  0.06)  
 Family CV history 30.9% -0.36 (-1.01;  0.28)  
 Alcohol intake ≥ 14 units per 
week 
14.6% 0.07 (-0.75;  0.89)  
 Cumulative of CV risk factors?  -1.11 (-1.36; -0.86) * 
CI, confidence interval; CVA, cerebrovascular accident; COPD, chronic obstructive 
pulmonary disease; CV, cardiovascular; TIA, transient ischemic attack 
* p < 0.01 
† Compared to patients with at least 5 to 7 days per week with 30 min of moderate physical 
activity. 
‡ Compared to non-smokers. 
§Cumulative comorbidities including only significant comorbidities. 
? Cumulative CV risk factors including only significant CV risk factors 
# Only available in 1305 patients and therefore not included in cumulative comorbidities. 
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Supplement Figure 1 
Methods 
 
1. Step: Imputation 
 
The following variables were imputed with multiple imputation (5 imputations, 10 iterations) with 
predictive mean matching for all variables using the function mice from mice package, R:  
 
Peak VO2, patient anthropometric data (age, height, BMI, waist circumference, sex, blood 
pressure), socio-behavioural factors (education, volunteer work, form of living), index procedure 
(CABG, PCI, valve, stable CAD without revascularization), cardiovascular risk factors (diabetes 
mellitus, smoking, hypertension, hypocholesteraemia, family history of CVD, alcohol 
consumption, physical inactivity), exercise limiting medication (beta blocker), comorbidities 
(nephropathy, rheumatic disease, chronic obstructive pulmonary disease, peripheral arterial 
disease, depression, obstructive sleep apnea, cerebrovascular accident), cardiac complaints 
(angina pectoris, chronic heart failure, arterial fibrillations, rhythm other than sinus, other 
complaints), cardiac disease history (previous CABG, PCI or ACS), resting heart and lung function 
(heart rate, forced vital capacity, forced expiratory volume in first second), haemoglobin and 
questionnaire scores (GAD sum score, PHQ9 sum score, Mediterranean diet score, mental 
component score of SF36). 
2. Step: Stepwise linear mixed model 
A stepwise backward variable selection was performed on each of the 5 imputed datasets with 
peak VO2 as response variable, center as random factor and all other variables mentioned in the 
list above as explanatory variables using step function from lmerTest package. The output of the 
resulting models for each imputed dataset is presented in the Figure below.  
 
Results and discussion 
The automatic stepwise backward variable selection and modeling on the imputed datasets 
resulted in 5 models comparable to the model presented in Figure 2 of the main article 
(Supplement Figure 1). Index intervention was removed from the models with the imputed data 
sets since this variable was no longer significant, most likely because haemoglobin remained in 
the models, which explained much of the difference between the different index interventions. 
Additionally, waist circumference was included instead of BMI, suggesting a stronger relationship 
of waist circumference with exercise capacity than BMI with exercise capacity. In the model 
presented in Figure 2 of the main article, waist circumference was omitted in favour of BMI 
because it was missing in 120 cases. 
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Supplement Figure 1: Mean effects of the mixed linear model for peak VO2 per body weight for 
the population with imputed data of 1633 patients. Shown are mean effects with 99% confidence 
intervals of the five imputed datasets. The model included continuous, binary and categorical 
independent variables. For categorical variables the according reference category is indicated. 
FEV1, forced expiratory volume in the first second; acs, acute coronary syndrome; CVD, 
cardiovascular disease; SF-36, Short Form Survey; PHQ, patient health questionnaire 
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Supplement Table 1: Generalised additive model for location, scale and shape for peak VO2 per body weight 
including data of 1282 patients (Nagelkerke R^2 = 0.52, Generalized AIC = 6721.48). 
Variable Estimate [99% CI] 
Intercept 
16.85 [11.86; 21.84] 
* 
Age [per decade] -0.08 [-0.13; -0.03] * 
Male Sex 1.70 [ 1.08;  2.32] * 
Procedure (Reference PCI)   
      No Intervention -0.04 [-1.13;  1.04]   
      Valve -1.08 [-1.85; -0.31] * 
      CABG -1.42 [-2.00; -0.84] * 
FEV1 [l/sec] 2.12 [ 1.68;  2.56] * 
Other Complaints -0.74 [-1.46; -0.02] * 
Ejection Fraction (Reference >55 %)   
      45-55 % -0.29 [-0.83;  0.25]   
      35-44 % -1.15 [-1.87; -0.43] * 
      <35 % -1.78 [-2.92; -0.65] * 
Angina Pectoris -1.06 [-2.09; -0.02] * 
Beta Blocker -0.82 [-1.40; -0.23] * 
Body Mass Index (Reference 18.5-24.9 
kg/m2) 
  
      <18.5 kg/m2 0.17 [-2.14;  2.49]   
      25-30 kg/m2 -1.27 [-1.81; -0.73] * 
      ≥30 kg/m2 -2.07 [-2.72; -1.42] * 
Diabetes Mellitus -0.74 [-1.27; -0.20] * 
Hypertension -0.70 [-1.20; -0.19] * 
Arterial Fibrillation -0.90 [-1.75; -0.06] * 
Nephropathy -1.25 [-2.11; -0.39] * 
Peripheral Artery Disease -1.05 [-1.88; -0.21] * 
Physical Activity [d/week] 0.24 [ 0.15;  0.32] * 
Mental Component Score SF-36 0.04 [ 0.02;  0.06] * 
Resting Heart Rate [per 10 pbm] -0.03 [-0.05; -0.01] * 
Diastolic BP [per 10 mmHg] 0.02 [ 0.00;  0.05] * 
CI, confidence interval; FEV1, forced expiratory volume in the first second; BP, 
blood pressure; PCI, percutaneous intervention; CABG, coronary artery bypass 
graft; NYHA, New York heart association; CVD, cardiovascular disease; SF-36, Short 
Form Survey. 
*p < 0.01 
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Supplement Table 2: Generalised additive model for location, scale and shape for peak VO2 per body weight 
including data of 1011 male patients (Nagelkerke R^2 = 0.50, Generalized AIC =  5358.41). 
Variable Estimate [99% CI] 
Intercept 19.44 [  13.76;  25.12] * 
Age [per decade] -0.09 [  -0.15;  -0.04] * 
Procedure (Reference PCI)   
      No Intervention 0.28 [  -1.25;   1.81]   
      Valve -1.16 [  -2.20;  -0.12] * 
      CABG -1.55 [  -2.19;  -0.90] * 
FEV1 [l/sec] 2.27 [   1.78;   2.76] * 
Other Complaints -0.87 [  -1.72;  -0.02] * 
Ejection Fraction (Reference >55 %)   
      45-55 % -0.19 [  -0.84;   0.47]   
      35-44 % -1.19 [  -2.05;  -0.32] * 
      <35 % -1.72 [  -3.09;  -0.34] * 
Angina Pectoris -1.14 [  -2.44;   0.15]   
Beta Blocker -0.93 [  -1.71;  -0.14] * 
Body Mass Index (Reference 18.5-24.9 
kg/m2) 
  
      <18.5 kg/m2 -5.24 [-285.78; 275.31]   
      25-30 kg/m2 -1.02 [  -1.71;  -0.33] * 
      ≥30 kg/m2 -1.98 [  -2.88;  -1.07] * 
Diabetes Mellitus -0.75 [  -1.36;  -0.14] * 
Hypertension -0.74 [  -1.32;  -0.15] * 
Arterial Fibrillation -0.99 [  -2.00;   0.01]   
Nephropathy -1.23 [  -2.34;  -0.12] * 
Peripheral Artery Disease -1.34 [  -2.27;  -0.41] * 
Physical Activity [d/week] 0.26 [   0.16;   0.36] * 
Mental Component Score SF-36 0.04 [   0.01;   0.07] * 
Resting Heart Rate [per 10 pbm] -0.04 [  -0.06;  -0.02] * 
Diastolic BP [per 10 mmHg] 0.02 [  -0.01;   0.05]  
CI, confidence interval; FEV1, forced expiratory volume in the first second; BP, 
blood pressure; PCI, percutaneous intervention; CABG, coronary artery bypass 
graft; CVD, cardiovascular disease; SF-36, Short Form Survey. 
*p < 0.01 
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Supplement Table 3: Generalised additive model for location, scale and shape for peak VO2 per body weight 
including data of 271 female patients (Nagelkerke R^2 = 0.44, Generalized AIC =  1389.38). 
Variable Estimate [99% CI] 
Intercept 14.22 [4.76; 23.68] 
Age [per decade] -0.06 [-0.15; 0.04] 
Procedure (Reference PCI)   
      No Intervention -0.55 [-2.43; 1.33] 
      Valve -1.17 [-2.62; 0.28]* 
      CABG -0.99 [-2.38; 0.40] 
FEV1 [l/sec] 2.42 [1.31; 3.53] 
Other Complaints -0.55 [-1.97; 0.88] 
Ejection Fraction (Reference >55 %)   
      45-55 % -0.42 [-1.53; 0.69] 
      35-44 % -0.68 [-2.33; 0.98]* 
      <35 % -1.46 [-4.04; 1.12] 
Angina Pectoris -1.11 [-2.98; 0.76] 
Beta Blocker -0.65 [-1.81; 0.51] 
Body Mass Index (Reference 18.5-24.9 
kg/m2) 
  
      <18.5 kg/m2 -0.56 [-3.26; 2.14] 
      25-30 kg/m2 -1.63 [-2.77; -0.49] 
      ≥30 kg/m2 -2.24 [-3.41; -1.07] 
Diabetes Mellitus -0.82 [-2.03; 0.40] 
Hypertension -0.50 [-1.55; 0.55]* 
Arterial Fibrillation -1.37 [-3.11; 0.36]* 
Nephropathy -0.91 [-3.11; 1.29] 
Peripheral Artery Disease -0.02 [-2.13; 2.09] 
Physical Activity [d/week] 0.17 [-0.01; 0.34] 
Mental Component Score SF-36 0.03 [-0.01; 0.07] 
Resting Heart Rate [per 10 pbm] -0.02 [-0.07; 0.02] 
Diastolic BP [per 10 mmHg] 0.03 [-0.01; 0.07] 
CI, confidence interval; FEV1, forced expiratory volume in the first second; BP, 
blood pressure; PCI, percutaneous intervention; CABG, coronary artery bypass 
graft; CVD, cardiovascular disease; SF-36, Short Form Survey. 
*p < 0.01 
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